Last reviewed · How we verify
Tinzaparin, Low dose prophylactic anticoagulation
At a glance
| Generic name | Tinzaparin, Low dose prophylactic anticoagulation |
|---|---|
| Also known as | LD-PA |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (PHASE4)
- Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (PHASE4)
- Therapeutic Anticoagulation Strategy for Acute Chest Syndrome (PHASE3)
- Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial (PHASE4)
- Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) (PHASE4)
- Hamburg Edoxaban for Anticoagulation in COVID-19 Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |